These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8294859)

  • 41. Chronic deletion, escape from deletion and activation of mouse mammary tumor virus superantigen-reactive T cells in C57BL/10 mice.
    Dyson PJ; Elliott JI
    Eur J Immunol; 1999 May; 29(5):1456-66. PubMed ID: 10359099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deletion of CD4+ T cells by mouse mammary tumor virus (FM) superantigen with broad specificity of T cell receptor beta-chain variable region.
    Yoshimoto T; Nagase H; Nakano H; Matsuzawa A; Nariuchi H
    Virology; 1996 Sep; 223(2):387-91. PubMed ID: 8806576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection and characterization of mouse mammary tumor virus cell surface antigens: estimation of antigen abundance by protein A assay.
    Callis AH; Ritzi EM
    J Virol; 1980 Sep; 35(3):876-87. PubMed ID: 6252344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of 5-azacytidine on expression of DNA sequences homologous to ENV gene of murine mammary tumor virus in normal human lymphocytes].
    Kriukova IN; Lushnikova AA; Makhov PB
    Mol Gen Mikrobiol Virusol; 2002; (2):36-9. PubMed ID: 12180024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunization with a mouse mammary tumour virus envelope protein epitope protects against tumour formation without inhibition of the virus infection.
    Astori M; Karapetian O
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1935-9. PubMed ID: 9266991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of two V beta 7-specific viral superantigens.
    Ignatowicz L; Kappler JW; Marrack P; Scherer MT
    J Immunol; 1994 Jan; 152(1):65-71. PubMed ID: 8254207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interplays between mouse mammary tumor virus and the cellular and humoral immune response.
    Acha-Orbea H; Finke D; Attinger A; Schmid S; Wehrli N; Vacheron S; Xenarios I; Scarpellino L; Toellner KM; MacLennan IC; Luther SA
    Immunol Rev; 1999 Apr; 168():287-303. PubMed ID: 10399081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Superantigens and retroviral infection: insights from mouse mammary tumor virus.
    Held W; Acha-Orbea H; MacDonald HR; Waanders GA
    Immunol Today; 1994 Apr; 15(4):184-90. PubMed ID: 8198710
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function.
    Held W; Waanders GA; Acha-Orbea H; MacDonald HR
    J Exp Med; 1994 Dec; 180(6):2347-51. PubMed ID: 7525852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic.
    Astori M; Kraehenbuhl JP
    Mol Immunol; 1996 Sep; 33(13):1017-24. PubMed ID: 9010240
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity.
    Papiernik M; do Carmo Leite-de-MoraesM ; Pontoux C; Joret AM; Rocha B; Penit C; Dy M
    J Immunol; 1997 May; 158(10):4642-53. PubMed ID: 9144476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mouse mammary tumor virus associated antigens and superantigens--immuno-molecular correlates of neoplastic progression.
    Wei WZ; Gill RF; Wang H
    Semin Cancer Biol; 1993 Jun; 4(3):205-13. PubMed ID: 8391342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The 3' half of the mouse mammary tumor virus orf gene is not sufficient for its superantigen function in transgenic mice.
    Lambert JF; Acha-Orbea H; Kolb E; Diggelmann H
    Mol Immunol; 1993 Nov; 30(16):1399-404. PubMed ID: 8232325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo T cell response to viral superantigen. Selective migration rather than proliferation.
    Le Bon A; Lucas B; Vasseur F; Penit C; Papiernik M
    J Immunol; 1996 Jun; 156(12):4602-8. PubMed ID: 8648102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exogenous mouse mammary tumor virus (MMTV) infection induces endogenous MMTV sag expression.
    Xu L; Wrona TJ; Dudley JP
    Virology; 1996 Jan; 215(2):113-23. PubMed ID: 8560758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Establishment of a C3Hf mammary tumor cell line expressing endogenous mouse mammary tumor virus: antigenic and genetic relationships of this virus with highly oncogenic mouse mammary tumor viruses.
    Arthur LO; Lovinger GG; Schochetman G
    J Virol; 1979 Dec; 32(3):852-9. PubMed ID: 92576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Receptors on T cells escaping superantigen-mediated deletion lack special beta-chain junctional region structural characteristics.
    Pullen AM; Bogatzki LY
    J Immunol; 1996 Mar; 156(5):1865-72. PubMed ID: 8596038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses.
    Palmer LD; Saha B; Hodes RJ; Abe R
    J Immunol; 1996 Mar; 156(6):2112-8. PubMed ID: 8690899
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative flow cytometry of mouse mammary tumor virus envelope glycoprotein (gp52): alternative measures of hormone-mediated change in a viral cell surface antigen.
    Ritzi EM
    J Virol Methods; 1992 Oct; 40(1):11-30. PubMed ID: 1331158
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-exclusive Fas control and age dependence of viral superantigen-induced clonal deletion in lupus-prone mice.
    Papiernik M; Pontoux C; Golstein P
    Eur J Immunol; 1995 Jun; 25(6):1517-23. PubMed ID: 7542196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.